The Cancer Epidemiology Program (CEP) brings together 25 investigators from 11 Departments at Stanford and the Northern California Cancer Center (NCCC) in a collaborative approach to reducing the burden, incidence, mortality and morbidity of cancer through innovative and interdisciplinary epidemiologic research. This goal is accomplished through observational research in four areas: cancer surveillance;cancer etiology and risk assessment;early cancer detection;and cancer treatment, prognosis and quality of life. The study of disparities among racial/ethnic/cultural groups forms a theme cross cutting all of these areas.
The specific aims of the four targeted research areas are: ? Cancer surveillance: Describe cancer risk factors and spatial and temporal trends in cancer incidence and mortality;identify scientific hypotheses for further study;conduct methodologic studies to improve data quality;and gather data as new technologies and treatments are introduced into medical practice. ? Cancer etiology and risk assessment: Convene multidisciplinary expertise to study the complex interactions of molecular, genetic, behavioral and environment factors that affect cancer occurrence. ? Early detection of cancer: Evaluate the use of new technologies to detect cancers before they have spread and increase understanding of the risks and benefits of screening. ? Cancer care, prognosis and quality of life: Conduct observational studies of cancer treatments and other cancer care to determine their diffusion, utilization and effect on patient outcomes by characteristics of patients, providers and delivery systems. Identify genetic, molecular and other determinants of recurrence and survival in cancer patients, and factors related to quality of life for cancer patients and families.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-07
Application #
8475451
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
7
Fiscal Year
2013
Total Cost
$15,591
Indirect Cost
$4
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Denny, Sarah K; Yang, Dian; Chuang, Chen-Hua et al. (2016) Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility. Cell 166:328-42
Li, Jian; Pfeffer, Suzanne R (2016) Lysosomal membrane glycoproteins bind cholesterol and contribute to lysosomal cholesterol export. Elife 5:
Chuang, Jody C; Shrager, Joseph B; Wakelee, Heather A et al. (2016) Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy. Clin Ther 38:1567-76
Wanigatunga, Amal A; Sourdet, Sandrine S; LaMonte, Michael J et al. (2016) Physical impairment and body weight history in postmenopausal women: the Women's Health Initiative. Public Health Nutr 19:3169-3177
Zanganeh, Saeid; Hutter, Gregor; Spitler, Ryan et al. (2016) Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol 11:986-994
Hiniker, Susan M; Reddy, Sunil A; Maecker, Holden T et al. (2016) A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. Int J Radiat Oncol Biol Phys 96:578-88
Grüner, Barbara M; Schulze, Christopher J; Yang, Dian et al. (2016) An in vivo multiplexed small-molecule screening platform. Nat Methods 13:883-9
Chen, Frank W; Sundaram, Vandana; Chew, Thomas A et al. (2016) Advanced Stage Colorectal Cancer in Persons Younger Than 50 Years not Associated With Longer Duration of Symptoms or Time to Diagnosis. Clin Gastroenterol Hepatol :
Zhu, Gefei Alex; Lira, Ruth; Colevas, Alexander Dimitrios (2016) Discordance in routine second opinion pathology review of head and neck oncology specimens: A single-center five year retrospective review. Oral Oncol 53:36-41
Brady, Jennifer J; Chuang, Chen-Hua; Greenside, Peyton G et al. (2016) An Arntl2-Driven Secretome Enables Lung Adenocarcinoma Metastatic Self-Sufficiency. Cancer Cell 29:697-710

Showing the most recent 10 out of 278 publications